title: Emerging approaches to target tumor metabolism.
abstract: Therapeutic exploitation of the next generation of drugs targeting the genetic basis of cancer will require an understanding of how cancer genes regulate tumor biology. Reprogramming of tumor metabolism has been linked with activation of oncogenes and inactivation of tumor suppressors. Well established and emerging cancer genes such as MYC, IDH1/2 and KEAP1 regulate tumor metabolism opening up opportunities to evaluate metabolic pathway inhibition as a therapeutic strategy in these tumors.
authors.affiliation: Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Ross
authors.affiliation: Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. Electronic address: Susan.Critchlow@astrazeneca.com.
authors.forename: Susan E
authors.initials: SE
authors.lastname: Critchlow
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D015195:Drug Design; D004734:Energy Metabolism / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor